anti-thyroglobulin autoantibodies (1/1600). She also had antimitochondrial IgG (greater than 1/640) and rheumatoid factor (1/40). Her serum thyroid stimulating hormone (Amerlite immunometric assay) was 3 0 mU/l (reference range: 0 15-3-2 mU/l) and her serum total T3 (Amerlex-M T3 radioimmunoassay) was 1 6 nmol/l (0-8-2-5 nmol/l), but her serum FT4 (Amerlite MAB FT4 assay) was unexpectedly and inappropriately high: 92 pmol/l (10-27 pmol/l). This spuriously high FT4 was found on assaying subsequent serum samples from the patient over a period of one year. Her serum albumin was 35 g/l, total protein was 68 g/l, and serum protein electrophoresis was normal. The patient was receiving the following medication during the period concerned: tolbutamide, metformin, isosorbide mononitrate, glyceryl trinitrate, diltiazem, cimetidine, digoxin, spironolactone, calciferol, hydroxyapatite and bisacodyl. To exclude possible interference from some of the patient's other autoantibodies positive control antigens against mitochondrial, rheumatoid factor, thyroid microsomal and thyroglobulin antibodies were separately added to the patient's serum before the FT4 assay. There was no reduction in the FT4 concentration after correcting for dilution with any of the above positive control antigens. Hence her autoantibodies to the above control antigens were unlikely to be the cause of her spuriously high FT4.
Conclusion
The above experimental results suggest that the spuriously high FI4 obtained from this patient was due to the presence of antithyroid hormone autoantibodies which recognise the T3 on the modified well surface. Anti-thyroid hormone autoantibodies may interfere with the measurement of FT4 in the Amerlite MAB FT4 assay, as well as the Amerlex MAB FT4 assay.
